21:16 , May 6, 2019 |  BC Extra  |  Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a...
19:10 , Oct 26, 2018 |  BC Week In Review  |  Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...
18:58 , Sep 21, 2018 |  BC Week In Review  |  Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases. Jenrin will receive $250,000 upfront and is...
22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
04:00 , Oct 28, 2017 |  BioCentury  |  Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
07:00 , Mar 10, 2014 |  BioCentury  |  Strategy

Abiding its time

Abide Therapeutics Inc. 's option deal with Celgene Corp. gives it several years to validate its serine hydrolase platform. Should Celgene opt to license ex-U.S. rights to Abide's lead inflammation programs rather than buy the...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Abide Therapeutics, Celgene deal

Celgene paid Abide $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing investor Cardinal Partners made a $10...
01:10 , Mar 1, 2014 |  BC Extra  |  Top Story

Abide grants Celgene options

Celgene Corp. (NASDAQ:CELG) paid Abide Therapeutics Inc. (Princeton, N.J.) $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing...
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Fatty acid amide hydrolase (FAAH) Mouse studies suggest inhibiting anandamide signaling through FAAH could help treat or prevent pulmonary hypertension. In isolated, perfused...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Cannabinoid CB1 receptor (CNR1) Cell culture and mouse studies suggest inhibiting CNR1 could help treat hyperinsulinemia in type 2 diabetes. In cultured rat...